Exhaled Air Biomarkers in COPD

慢性阻塞性肺病 (COPD) 中的呼出空气生物标志物

• 批准号: 6780965
• 负责人: NORBERT F VOELKEL
• 金额: $ 31.7万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-26 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6780965
• 关键词: adult human (21+); apoptosis; biomarker; chronic obstructive pulmonary disease; clinical research; eicosanoids; human subject; inflammation; mass spectrometry; method development; necrosis; nucleosides; oxidative stress; patient oriented research; peptides; phenotype; phospholipids; proteins; pulmonary respiration; respiratory disease /disorder therapy; sample collection; spirometry; stable isotope; steroids; ultrafiltration

DESCRIPTION (provided by applicant): COPD is a world-wide health problem of increasing prevalence. Non-invasive markers of disease phenotype, severity and rate of progression of the disease, markers characterizing exacerbations of COPD are badly needed. We propose to analyze ultrafiltered exhaled air samples, to establish optimal protocols for sample collection following a FEV1 maneuver, to survey lipids including phospholipids, eicosanoids, steroids, nucleosides, proteins and peptides as markers of potential disease (activity). We propose to establish quantitative mass spectroscopic techniques (using stable isotope dilution protocols) for target marker assays. We propose to investigate stable COPD patients before and during supplemental continuous flow oxygen treatment, before and during alpha-l-antitrypsin infusion therapy, before and after smoking cessation and before and after lung transplantation.

描述（由申请人提供）： 慢性阻塞性肺病是一个日益流行的世界性健康问题。 迫切需要疾病表型、疾病严重程度和进展速度的非侵入性标记物、表征 COPD 恶化的标记物。 我们建议分析超滤呼出空气样本，建立 FEV1 操作后样本采集的最佳方案，调查脂质（包括磷脂、类二十烷酸、类固醇、核苷、蛋白质和肽）作为潜在疾病（活动）的标志物。 我们建议建立用于目标标记测定的定量质谱技术（使用稳定同位素稀释方案）。 我们建议在补充持续流氧治疗之前和期间、α-l-抗胰蛋白酶输注治疗之前和期间、戒烟之前和之后以及肺移植之前和之后对稳定的慢性阻塞性肺病患者进行调查。